secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2026-05-11T20:05:19+00:00
Accession:  0001193125-26-216739
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca posts Q1 net loss of $183.4M; cash $408.5M; advances ERAS-0015 with robust early data
--------------------------------------------------------------------------------

- Net loss of $183.4M ($0.60 per share) vs $31.0M loss a year ago; includes $150M in-process R&D charge for license expansion.
- Cash and securities of $408.5M as of Mar 31, 2026, expected to fund ops into H2 2028; completed $258.8M public offering in Jan.
- ERAS-0015 dose escalation showed robust responses in KRAS G12X NSCLC and PDAC with favorable safety; no TRAE discontinuations.
- Monotherapy expansion and combo with panitumumab initiated ahead of schedule; data expected H1 2027.
- Entered CTCSA with Merck for ERAS-0015 + KEYTRUDA combo; also with Tango for PRMT5 inhibitor combo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526216739/0001193125-26-216739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526216739/eras-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer